SR 202
- CAS No.
- 76541-72-5
- Chemical Name:
- SR 202
- Synonyms
- SR 202;MIFOBATE;Clenicor;claniclor;SR-202 >=98% (HPLC), crystalline;Dimethyl (α-dimethoxyphosphinyl-p-chlorobenzyl) phosphate;DIMETHYL (ALPHA-DIMETHOXYPHOSPHINYL-P-CHLOROBENZYL) PHOSPHATE;(4-Chlorophenyl)(dimethoxyphosphoryl)methyl dimethyl phosphate;[(4-Chlorophenyl)(dimethoxyphosphinyl)methyl]dimethyl=phosphate;Dimethyl (α-dimethoxyphosphinyl-p-chlorobenzyl) phosphate, Mifobate
- CBNumber:
- CB4285085
- Molecular Formula:
- C11H17ClO7P2
- Molecular Weight:
- 358.65
- MDL Number:
- MFCD01748280
- MOL File:
- 76541-72-5.mol
| Boiling point | 436.6±45.0 °C(Predicted) |
|---|---|
| Density | 1.355±0.06 g/cm3(Predicted) |
| storage temp. | Inert atmosphere,Store in freezer, under -20°C |
| solubility | DMSO: 5 mg/mL |
| form | crystalline |
| color | white |
| Water Solubility | Soluble to 100 mM in water |
| FDA UNII | ZKA4OVV12E |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P301+P312-P302+P352-P304+P340-P305+P351+P338 | |||||||||
| Safety Statements | 22-24/25 | |||||||||
| WGK Germany | 2 | |||||||||
| RTECS | TB8817000 | |||||||||
| NFPA 704 |
|
SR 202 price More Price(19)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 21846 | SR 202 ≥95% | 76541-72-5 | 1mg | $45 | 2024-03-01 | Buy |
| Cayman Chemical | 21846 | SR 202 ≥95% | 76541-72-5 | 5mg | $133 | 2024-03-01 | Buy |
| Tocris | 2022 | SR202 ≥99%(HPLC) | 76541-72-5 | 10 | $151 | 2021-12-16 | Buy |
| Tocris | 2022 | SR202 ≥99%(HPLC) | 76541-72-5 | 50 | $616 | 2021-12-16 | Buy |
| Usbiological | 256741 | SR 202 | 76541-72-5 | 10mg | $389 | 2021-12-16 | Buy |
SR 202 Chemical Properties,Uses,Production
Description
SR 202 is an effective and specific PPARγ antagonist that selectively inhibits the transcriptional activity of PPARγ induced by TZD (IC50=140 μM). Sr-202 does not affect basal or ligand stimulated transcriptional activity of PPARα, PPARβ, or FXR. It has anti-obesity and anti-diabetes effects.
Uses
Anti-atherosclerotic.
Uses
SR 202 is a noniodinated, potential lipid-altering agent and an inhibitor of the peripheral conversion of T4 to T3 associated with thyroid hormone metabolism.
Definition
ChEBI: Phosphoric acid [(4-chlorophenyl)-dimethoxyphosphorylmethyl] dimethyl ester is a trialkyl phosphate.
brand name
Clenicor (Symphar S.A.,Switzerland).
Biological Activity
Selective PPAR γ antagonist; antidiabetic and antiobesity agent. Attenuates troglitazone-induced PPAR γ transcriptional activity (IC 50 = 140 μ M) without affecting ligand-stimulated PPAR α , PPAR β or FXR transcriptional activity. Inhibits PPAR γ -dependent adipocyte differentiation and growth in vitro and in vivo . Improves insulin sensitivity in diabetic ob/ob mice and increases HDL levels in rats in vivo .
in vitro
sr-202 is a specific antagonist of ppar, which shows selectivity both among the ppar family members and other nuclear receptors. sr-202 also inhibits ppar-dependent differentiation of adipocytes. in cell culture, sr-202 efficiently antagonizes hormone- and tzd induced adipocyte differentiation [1].
in vivo
. decreasing ppar activity by treatment with sr-202 leads to a reduction of both high fat diet-induced adipocyte hypertrophy and insulin resistance. treatment with sr-202 also dramatically improves insulin sensitivity in the diabetic ob/ob mice [1]. when wild-type mice are fed a high-fat diet, the plasma levels of tnf-α are raised, and sr-202 treatment protects against this rise [2]..
IC 50
140 μm for attenuation of troglitazone-induced peroxisome proliferator-activated receptor gamma (ppar) transcriptional activity [1]
storage
Desiccate at RT
References
[1] rieusset j, touri f, michalik l, escher p, desvergne b, niesor e, wahli w. a new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. mol endocrinol. 2002 nov;16(11):2628-44.
[2] doggrell s. do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs expert opin investig drugs. 2003 apr;12(4):713-6.
SR 202 Preparation Products And Raw materials
Raw materials
Preparation Products
SR 202 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 | marketing@targetmol.com | United States | 19892 | 58 |
| Hangzhou MolCore BioPharmatech Co.,Ltd. | +86-057181025280; +8617767106207 | sales@molcore.com | China | 49739 | 58 |
| Aladdin Scientific | +1-+1(833)-552-7181 | sales@aladdinsci.com | United States | 57511 | 58 |
| 3B Pharmachem (Wuhan) International Co.,Ltd. | 821-50328103-801 18930552037 | 3bsc@sina.com | China | 15848 | 69 |
| Shanghai Synchem Pharma Co., ltd | 21-619849051-1 18521059765 | synchempharma@aliyun.com | China | 6443 | 55 |
| EMMX Biotechnology LLC | 888-539-0666 | info@emmx.com | United States | 8449 | 60 |
| Tianjin Kailiqi Biotechnology Co., Ltd. | 15076683720 | klq@cw-bio.com | China | 3770 | 55 |
| Aikon International Limited | 025-58851090 13611564524 | lwan@aikonchem.com | China | 15952 | 58 |
| Fan De(Beijing) Biotechnology Co., Ltd. | 15911056312 | liming@bio-fount.com | China | 9730 | 58 |
| BOC Sciences | -- | info@bocsci.com | USA | 0 | 65 |